Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.48 |
| ▸ | KDM5A | P29375 | 5/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | KDM5C | P41229 | 3/20 | 0.47 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630367 | 0.95 | KDM4E (0.58) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL29038561 | 0.94 | LMNA (0.56) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL29038570 | 0.94 | LMNA (0.56) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL17873933 | 0.90 | KDM4E (0.73) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL16055788 | 0.85 | KDM5B (0.63) | KDM4ELMNACYP3A4TSHRKDM5B | |
| SCHEMBL16115747 | 0.85 | KDM4E (0.49) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL28093033 | 0.84 | KDM4E (0.84) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL28030800 | 0.84 | KDM5B (0.51) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| 2-Ethylisonicotinamide SCHEMBL2606610 | 0.83 | CYP1A2 (0.69) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL5147899 | 0.81 | TSHR (0.51) | KDM4ELMNACYP3A4TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-108473462-A | Pyrazoles-pyridine derivate as EAAT3 inhibitor | 豪夫迈·罗氏有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-107922381-A | PYRIDINE OR PYRIMIDINE DERIVATIVES | 豪夫迈·罗氏有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107709311-A | The carboxamides derivatives of 2 phenyl, 6 imidazolyl pyridines 4 and its purposes as EAAT3 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| CN-101679418-A | [2,6] naphthyridines compounds as protein kinase inhibitors | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2144909-A1 | [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | KDM4E 4332/4885LMNA 1368/4885CYP3A4 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.